Get the Stockscreener App
14.58
0.00%
0.00
After Hours:
14.59
0.010
+0.07%
Arcutis Biotherapeutics Inc stock is traded at $14.58, with a volume of 1.16M.
It is up +0.00% in the last 24 hours and up +3.99% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$14.58
Open:
$14.37
24h Volume:
1.16M
Relative Volume:
0.64
Market Cap:
$1.74B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.7194
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-2.93%
1M Performance:
+3.99%
6M Performance:
+10.12%
1Y Performance:
+44.79%
1-Day Range:
$14.31
$14.66
1-Week Range:
$14.31
$15.38
52-Week Range:
$7.86
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.58 | 1.74B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
What are the technical indicators suggesting about Arcutis Biotherapeutics Inc.Retirement Planning Insights For 2025 - jammulinksnews.com
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Why Arcutis Biotherapeutics Inc. stock attracts strong analyst attentionDay Trading Signals With High Precision Reviewed - beatles.ru
How Arcutis Biotherapeutics Inc. stock performs during market volatilityLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Arcutis Biotherapeutics Inc. Stock Lags Behind Sector BenchmarksPotential Breakout Stock List Published This Week - metal.it
Published on: 2025-07-29 00:51:18 - metal.it
What catalysts could drive Arcutis Biotherapeutics Inc. stock higher in 2025Post Market Opportunities For Consistent Profits - jammulinksnews.com
Is Arcutis Biotherapeutics Inc. a growth stock or a value stockFree Stock Target Finder That Work - jammulinksnews.com
Does Arcutis Biotherapeutics Inc. stock perform well during market downturnsInvest smarter and grow your wealth faster - jammulinksnews.com
What are analysts’ price targets for Arcutis Biotherapeutics Inc. in the next 12 monthsAchieve rapid wealth accumulation with smart picks - jammulinksnews.com
How volatile is Arcutis Biotherapeutics Inc. stock compared to the marketGet timely alerts on market opportunities - jammulinksnews.com
What are the latest earnings results for Arcutis Biotherapeutics Inc.Exceptional stock performance - jammulinksnews.com
Is it the right time to buy Arcutis Biotherapeutics Inc. stockOutstanding growth strategies - jammulinksnews.com
What institutional investors are buying Arcutis Biotherapeutics Inc. stockOutstanding stock performance - jammulinksnews.com
When is Arcutis Biotherapeutics Inc. stock expected to show significant growthLightning-fast capital gains - jammulinksnews.com
Published on: 2025-07-27 18:07:10 - jammulinksnews.com
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - The Globe and Mail
What analysts say about Arcutis Biotherapeutics Inc. stockOver 200% growth - PrintWeekIndia
Goldman Sachs Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Neutral Recommendation - MSN
Goldman Sachs Initiates Coverage On Arcutis Biotherapeutics (ARQ - GuruFocus
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Is Arcutis Biotherapeutics Inc. a good long term investmentRecord-setting profit potential - PrintWeekIndia
Arcutis Biotherapeutics initiated with a Neutral at Goldman Sachs - TipRanks
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 | ARQT Stock News - GuruFocus
Arcutis Earnings: Commercial-Stage Immuno-Dermatology Leader to Reveal Q2 2025 Performance - Stock Titan
Is Arcutis Biotherapeutics (NASDAQ:ARQT) Using Too Much Debt? - 富途牛牛
Arcutis Biotherapeutics Inc. Stock Analysis and ForecastExponential return rates - jammulinksnews.com
What drives Arcutis Biotherapeutics Inc. stock priceAccelerated wealth building - jammulinksnews.com
Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth - Investing.com India
(ARQT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):